Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Antimicrob Agents ; 31(1): 37-45, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18006283

RESUMO

Tuberculosis (TB) is a leading cause of death amongst infectious diseases. The low permeation of antimycobacterial agents and their difficult access to infected macrophages necessitate long-term use of high drug doses. Liposomes preferentially accumulate in macrophages, increasing the efficacy of antibiotics against intracellular parasites. In the present work, several rifabutin (RFB) liposomal formulations were developed and characterised and their in vivo profile was compared with free RFB following intravenous administration. With the RFB liposomal formulations tested, higher concentrations of the antibiotic were achieved in liver, spleen and lungs 24h post administration compared with free RFB. The concentration of RFB in these organs was dependent on the rigidity of liposomal lipids. The liposomal RFB formulation prepared with dipalmitoyl phosphatidylcholine:dipalmitoyl phosphatidylglycerol (DPPC:DPPG) was the most effective and was selected for biological evaluation in a mouse model of disseminated TB. Compared with mice treated with free RFB, mice treated with the DPPC:DPPG RFB formulation exhibited lower bacterial loads in the spleen (5.53 log(10) vs. 5.18 log(10)) and liver (5.79 log(10) vs. 5.41 log(10)). In the lung, the level of pathology was lower in mice treated with encapsulated RFB. These results suggest that liposomal RFB is a promising approach for the treatment of extrapulmonary TB in human immunodeficiency virus co-infected patients.


Assuntos
Antituberculosos/administração & dosagem , Rifabutina/administração & dosagem , Tuberculose/tratamento farmacológico , Animais , Antituberculosos/farmacocinética , Antituberculosos/uso terapêutico , Química Farmacêutica , Lipossomos , Fígado/química , Fígado/microbiologia , Pulmão/química , Pulmão/microbiologia , Pulmão/patologia , Camundongos , Camundongos Endogâmicos BALB C , Rifabutina/farmacocinética , Rifabutina/uso terapêutico , Baço/química , Baço/microbiologia , Fatores de Tempo
2.
J Biomed Nanotechnol ; 10(12): 3647-57, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26000378

RESUMO

Main-stay in treatment of leishmaniasis relies on chemotherapy but none of the current drugs combines high activity and low toxicity at affordable costs. Dinitroanilines are a new class of drugs with proved in vitro antileishmanial activity. However the development of their pharmaceutical formulations has been compromised by low water solubility and low accumulation in diseased organs. These limitations can be overcome by incorporation in lipid-based nanoformulations such as liposomes and solid lipid nanoparticles. In previous work this strategy was already followed with the incorporation of a dinitroaniline, oryzalin, resulting in the improvement of the biodistribution profile. The present work aims at demonstrating the in vitro and in vivo therapeutic activity of these oryzalin nanoformulations, and establishing a systematic comparison of both systems. After oryzalin incorporation suitable physicochemical properties for parenteral administration were obtained. Nanoformulations revealed reduced cytotoxicity and haemolytic activity when compared with free-oryzalin, while retaining the in vitro intracellular activity. Therapeutic activity, assessed in a murine model of visceral leishmaniasis, was evaluated in terms of number of administrations, dose-response and influence of the lipid excipient. Results demonstrate the superiority of both oryzalin nanoformulations on the reduction of parasitic burden in liver and spleen as compared to the control group (84 to 91%) and similar to Glucantime. A strong reduction in ED50 values (3 to 65 fold) as compared to free-oryzalin was also obtained, depending on the organ and nanoformulation used. Both oryzalin nanoformulations are potential candidates as therapeutic agents against visceral leishmaniasis.


Assuntos
Dinitrobenzenos/administração & dosagem , Leishmania/efeitos dos fármacos , Leishmaniose/tratamento farmacológico , Leishmaniose/patologia , Lipídeos/química , Lipossomos/química , Nanocápsulas/química , Sulfanilamidas/administração & dosagem , Animais , Antiprotozoários/administração & dosagem , Antiprotozoários/química , Difusão , Dinitrobenzenos/química , Leishmania/citologia , Leishmania/fisiologia , Masculino , Teste de Materiais , Camundongos , Camundongos Endogâmicos BALB C , Nanocápsulas/administração & dosagem , Nanocápsulas/ultraestrutura , Sulfanilamidas/química , Resultado do Tratamento
3.
Eur J Pharm Sci ; 45(4): 442-50, 2012 Mar 12.
Artigo em Inglês | MEDLINE | ID: mdl-21983568

RESUMO

Oryzalin is a dinitroaniline drug that has attracted recent interest for the treatment of leishmaniasis. Its use as an antiparasitic therapeutic agent is limited by the low water solubility associated with an in vivo rapid clearance, leading to the administration of larger and possibly toxic doses in in vivo studies, and the use of solvents that may lead to undesirable side effects. In the present work oryzalin-containing lipid nanoparticles were produced by a emulsion-solvent evaporation technique using a composition suitable for parenteral administration, i.e., tripalmitin (solid lipid) and a complex mixture of three emulsifying agents (soya lecithin, Tween® 20 and sodium deoxycholate). Physicochemical characterization included the determination of mean particle size, polydispersity index, zeta potential, encapsulation efficiency and DSC studies. Final formulations revealed values of <140 nm (PI<0.2) and zeta potential of ≈-35 mV, as well as encapsulation efficiency >75%. The effects of various processing parameters, such as lipid and surfactant and composition and concentration, as well as the stability during the harsh procedures of autoclaving (121°C/15 min) and freeze-drying were also evaluated. Formulations revealed to be stable throughout freeze-drying and moist-heath sterilization without significant variations on physicochemical properties and no significant oryzalin losses. The use of a complex surfactant mixture proved crucial for preserving formulation stability. Particularly, lecithin appears as a key component in the stabilization of tripalmitin-based oryzalin-containing lipid nanoparticles. Finally, cell viability studies demonstrated that the incorporation of oryzalin in nanoparticles decreases cytotoxicity, thus suggesting this strategy may improve tolerability and therapeutic index of dinitroanilines.


Assuntos
Antiprotozoários/química , Dinitrobenzenos/química , Nanopartículas/química , Polissorbatos/química , Sulfanilamidas/química , Antiprotozoários/farmacologia , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Ácido Desoxicólico/química , Dinitrobenzenos/farmacologia , Estabilidade de Medicamentos , Humanos , Lecitinas/química , Leishmaniose , Tamanho da Partícula , Polissorbatos/farmacologia , Sulfanilamidas/farmacologia , Propriedades de Superfície , Tensoativos/química , Triglicerídeos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA